Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants With Anemia Due to Low-risk Myelodysplastic Syndrome
Conditions
Interventions
Momelotinib
Locations
1
United States
GSK Investigational Site
Canton, Ohio, United States
Start Date
June 5, 2025
Primary Completion Date
June 3, 2027
Completion Date
March 6, 2029
Last Updated
June 27, 2025
NCT07270978
NCT05292664
NCT06499285
NCT04953910
NCT04953897
NCT05350748
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions